Neuronetics Dirección

Dirección controles de criterios 1/4

El CEO de Neuronetics' es Keith Sullivan , nombrado en Jul 2020, tiene una permanencia de 3.75 años. compensación anual total es $2.99M, compuesta por 23.4% salario y 76.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.21% de las acciones de la empresa, por valor de $2.48M. La antigüedad media del equipo directivo y de la junta directiva es de 1.2 años y 3.9 años, respectivamente.

Información clave

Keith Sullivan

Chief Executive Officer (CEO)

US$3.0m

Compensación total

Porcentaje del salario del CEO	23.4%
Permanencia del CEO	3.8yrs
Participación del CEO	2.2%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

May 01

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Mar 17

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Aug 29

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Aug 02

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

Jul 19

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

Jun 08

Is Neuronetics (NASDAQ:STIM) Weighed On By Its Debt Load?

Jan 19

Is Neuronetics (NASDAQ:STIM) Using Debt In A Risky Way?

Oct 14

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Keith Sullivan en comparación con los beneficios de Neuronetics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$3m	US$700k	-US$30m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$31m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$2m	US$676k	-US$37m
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	n/a	n/a	-US$37m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$3m	US$650k	-US$31m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$4m	US$280k	-US$27m

Compensación vs. Mercado: La compensación total de Keith($USD2.99M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD677.87K).

Compensación vs. Ingresos: La compensación de Keith ha aumentado mientras la empresa no es rentable.

CEO

Keith Sullivan (65 yo)

3.8yrs

Permanencia

US$2,990,985

Compensación

Mr. Keith J. Sullivan has been President, Chief Executive Officer and Director of Neuronetics, Inc. since July 14, 2020. Mr. Sullivan has been a Director of Venus Concept Inc. (formerly known as Restoratio...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Keith Sullivan	President	3.8yrs	US$2.99m	2.21% $ 2.4m
Stephen Furlong	Executive VP	4.8yrs	US$1.36m	0.85% $ 906.1k
W. Macan	Executive VP	4.3yrs	US$1.16m	0.60% $ 641.6k
Rusty Page	Senior VP of Operations & Quality	1.3yrs	sin datos	sin datos
Lisa Metzner-Rosas	Senior VP & Chief Marketing Officer	less than a year	sin datos	sin datos
Sara Grubbs	Senior VP & Chief Revenue Officer	1.3yrs	sin datos	sin datos
Rick Grubbs	Senior Vice President of National Accounts	1.3yrs	sin datos	sin datos
Cory Anderson	Senior Vice President of R&D and Clinical	1.3yrs	sin datos	sin datos

1.3yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de STIM no se considera experimentado ( 1.2 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Keith Sullivan	President	3.8yrs	US$2.99m	2.21% $ 2.4m
Glenn Muir	Independent Director	6.8yrs	US$182.50k	0.43% $ 456.0k
Wilfred Jaeger	Independent Director	19yrs	US$162.50k	0.34% $ 363.3k
Sheryl Conley	Independent Director	4.6yrs	US$175.00k	0.26% $ 279.4k
John Bakewell	Independent Director	4.1yrs	US$180.00k	0.26% $ 277.2k
Robert Cascella	Independent Chairman of the Board	3.1yrs	US$245.00k	0.30% $ 316.0k
Joseph Capper	Director	1.3yrs	US$165.00k	0.023% $ 24.1k
Megan Rosengarten	Independent Director	2.8yrs	US$162.50k	0.17% $ 176.1k

4.0yrs

Permanencia media

63yo

Promedio de edad

Junta con experiencia: La junta directiva de STIM se considera experimentada (3.9 años de antigüedad promedio).

Neuronetics Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Executive VP notifies of intention to sell stock

President recently sold US$71k worth of stock

President notifies of intention to sell stock

Executive VP recently sold US$53k worth of stock

Executive VP notifies of intention to sell stock

Executive VP recently sold US$52k worth of stock

Recent updates

Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?

Neuronetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation

Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely

Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024

Full year 2023 earnings released: US$1.05 loss per share (vs US$1.38 loss in FY 2022)

Executive VP notifies of intention to sell stock

President recently sold US$71k worth of stock

President notifies of intention to sell stock

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Neuronetics, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Executive VP recently sold US$53k worth of stock

Executive VP notifies of intention to sell stock

Executive VP recently sold US$52k worth of stock

Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System

Executive VP notifies of intention to sell stock

Neuronetics: Modest Improvements Are Not Enough

President recently sold US$60k worth of stock

Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023

Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward

Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory

Neuronetics, Inc. Announces Pharmaceuticals and Medical Devices Agency Approval in Japan

New minor risk - Share price stability

Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neuronetics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Neuronetics, Inc. Announces the Launch of the NeuroStar Voices Portal

Consensus EPS estimates upgraded to US$1.15 loss

Neuronetics, Inc. Provides Revenue Guidance for the Third Quarter of 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations

Neuronetics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuronetics, Inc Announces Expanded TMS Therapy Access Through Aetna® Health Plans

Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story

Neuronetics Receives 510(K) Clearance for Ocd Mt Cap for Neurostar Advanced Therapy

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2023

Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?

Executive VP recently sold US$58k worth of stock

Executive VP notifies of intention to sell stock

Price target decreased by 10% to US$8.67

President recently sold US$214k worth of stock

President notifies of intention to sell stock

Neuronetics Announces Elevation of Sara Grubbs to SVP, Chief Revenue Officer

High number of new directors

Neuronetics, Inc. Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar(R) Advanced Therapy for Mental Health

Neuronetics, Inc. Revised Revenue Guidance for the Fourth Quarter and Full Year of 2022

Neuronetics, Inc. Appoints Joseph H. Capper to Its Board of Directors and as Member of the Audit Committee, Effective January 1, 2023

Consensus estimates of losses per share improve by 10%

Neuronetics, Inc. Announces New Advancements of NeuroStar Advanced Therapy System

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

President exercised options to buy US$341k worth of stock.

Neuronetics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Neuronetics, Inc. Launches Innovations to Neurostar Advanced Therapy’s Proprietary Trakstar Platform

Neuronetics: Growth To Capture, But Fairly Priced

Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?

Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression

Bruce J. Shook Notifies the Board of Directors of Neuronetics, Inc. to Resign from the Board Effective as of October 31, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Neuronetics, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2022 and for the Year Ending December 31, 2022

Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance

Senior VP notifies of intention to sell stock

President recently sold US$236k worth of stock

Neurostics Inc. Receives U.S. Food and Drug Administration Clearance for Treatment of Anxious Depression

Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression

President notifies of intention to sell stock

Cannell Capital LLC Communicates with Neuronetics Inc

Is Neuronetics (NASDAQ:STIM) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind